{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"data_sharing_plan":["IPD Sharing (as of March 2023): No"],"condition":["HER2-positive Colorectal Cancer","HER2-positive Gastric Cancer","HER2 Low Breast Cancer","HER2-positive Tumors","HER2-positive Non-Small Cell Lung Cancer","Breast Neoplasms","HER2-positive Breast Cancer"],"disease":["Her2-positive Tumors","Her2-positive Non-small Cell Lung Cancer","Her2-positive Colorectal Cancer","Her2-positive Gastric Cancer","Her2 Low Breast Cancer","Her2-positive Breast Cancer","Breast Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2746280"],"location":["United States"],"study_start_month":["1"],"repository":["ECRIN MDR"],"study_status":["Suspended"],"additional_accession":[]},"is_claimable":false,"name":"A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2","description":"A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.","dates":{"creation":"2023-01-15"},"accession":"2746280","cross_references":{"ClinicalTrials___gov":["NCT05514717"]}}